Headlines about Fresenius Medical Care (NYSE:FMS) have trended somewhat positive on Monday, Accern Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Fresenius Medical Care earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.6009101814674 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern’s scoring:
- Fresenius Medical Care Corporation (FMS) Given Average Recommendation of “Hold” by Analysts (americanbankingnews.com)
- Here’s Why You Should Offload Fresenius Medical Stock Now (zacks.com)
- Fresenius Medical Care AG & Co. KGaA :FMS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 22, 2017 (finance.yahoo.com)
- Fresenius gets in on $3m Modulated Imaging Series A (massdevice.com)
- Capital Square 1031 Completes Two DST Offerings of Medical Office Buildings in North Carolina (finance.yahoo.com)
Several research firms have recently issued reports on FMS. Zacks Investment Research lowered shares of Fresenius Medical Care from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. DZ Bank AG reissued a “buy” rating on shares of Fresenius Medical Care in a research note on Monday, November 13th. Royal Bank Of Canada reissued a “hold” rating and set a $44.00 target price on shares of Fresenius Medical Care in a research note on Wednesday, September 13th. Finally, BidaskClub lowered shares of Fresenius Medical Care from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $48.50.
Fresenius Medical Care (NYSE:FMS) traded up $0.44 on Monday, hitting $49.36. 84,200 shares of the company traded hands, compared to its average volume of 180,851. Fresenius Medical Care has a 52-week low of $38.20 and a 52-week high of $50.22. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.98 and a current ratio of 1.22. The firm has a market cap of $30,392.04, a P/E ratio of 22.13, a PEG ratio of 2.23 and a beta of 0.45.
Fresenius Medical Care Company Profile
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.